STRN-ALK rearrangement
STRN-ALK rearrangement
|
Mesothelioma
Mesothelioma
|
crizotinib
Sensitive: C4 – Case Studies
|
STRN-ALK rearrangement
STRN-ALK rearrangement
|
Mesothelioma
Mesothelioma
|
ABT 263
Sensitive: D – Preclinical
|
STRN-ALK rearrangement
STRN-ALK rearrangement
|
Mesothelioma
Mesothelioma
|
cobimetinib
Sensitive: D – Preclinical
|
STRN-ALK rearrangement
STRN-ALK rearrangement
|
Mesothelioma
Mesothelioma
|
ceritinib + PF-05212384
Sensitive: D – Preclinical
|
STRN-ALK rearrangement
STRN-ALK rearrangement
|
Mesothelioma
Mesothelioma
|
X-396
Sensitive: D – Preclinical
|
STRN-ALK rearrangement
STRN-ALK rearrangement
|
Mesothelioma
Mesothelioma
|
trametinib
Sensitive: D – Preclinical
|
STRN-ALK rearrangement
STRN-ALK rearrangement
|
Mesothelioma
Mesothelioma
|
cobimetinib + ceritinib
Sensitive: D – Preclinical
|
STRN-ALK rearrangement
STRN-ALK rearrangement
|
Mesothelioma
Mesothelioma
|
ceritinib
Sensitive: D – Preclinical
|
STRN-ALK rearrangement
STRN-ALK rearrangement
|
Mesothelioma
Mesothelioma
|
brigatinib
Sensitive: D – Preclinical
|
STRN-ALK rearrangement
STRN-ALK rearrangement
|
Mesothelioma
Mesothelioma
|
cisplatin + gemcitabine
Resistant: D – Preclinical
|
